Skip to content

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression

A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo, Flávia Vieira, Rodrigo P Mello, A. T. Caliman-Fontes, Mariana V F Echegaray, Roberta F. Marback, Lívia N F Guerreiro-Costa, Breno Souza-Marques, Cassio Santos-Lima, Lucca S. Souza, Igor D. Bandeira, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini

Human Psychopharmacology February 18, 2022 DOI: 10.1002/hup.2836 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Population People with treatment-resistant depression
Interventions Racemic ketamine Esketamine
Duration 24 hours and 7 days after infusion
Topics Depression Esketamine Ketamine
Citations 39
Key findings Clinical predictors of depressive symptom remission and response were identified 24 hours and 7 days after racemic ketamine and esketamine infusions.

Abstract

Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions.

Comparable studies

Other observational and cohort studies on esketamine for depression, most cited first.

Study Year Design Participants
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression Patients with treatment-resistant bipolar depression (B-TRD) and unipolar... 2023 Observational cohort n = 70
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. Adults with treatment-resistant depression 2023 Observational study n = 62
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) Treatment-resistant depression patients 2023 Retrospective, multicentric, real-world study n = 149
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study Patients with treatment-resistant depression and a substance use disorder 2023 Observational, retrospective, multicentre study n = 26
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group Adults aged 65 years or older with treatment-resistant depression 2023 Post-hoc analysis of a multicenter, retrospective, observational study n = 30

Related reading

Explore topics

Depression Esketamine Ketamine

By condition and practice

Esketamine for depression Ketamine for depression